Cochlear shares have been one of the ASX 200's most painful stories of 2026, and the full-year result is now days away.
Cochlear Ltd (ASX: COH) reports its FY26 numbers on 18 August.
Expectations have been reset dramatically since April.
Let's look at what needs to go right.
Image source: Getty Images
Why Cochlear shares fell so hard
The turning point came on 22 April.
Cochlear cut its FY26 underlying net profit guidance to $290 million to $330 million, down from $435 million to $460 million.
That is a downgrade of roughly 30% at the midpoint.
The original guidance had been reaffirmed only two months earlier, and as such, the market's response was brutal.
The stock plunged 40.7% in a single trading session, its worst one-day decline on record.
Management pointed to several converging pressures.
Cochlear implant volumes softened across developed markets, hospital capacity constraints bit in Europe, referral activity slowed, and a stronger Australian dollar added a foreign exchange headwind.
Conflict in the Middle East also led to cancelled orders and delayed deliveries.
Recent earnings: what the half-year showed
The first half already carried warning signs, though few read them that way at the time.
Cochlear delivered underlying net profit of about $195 million for the six months to 31 December 2025, down 9% year-on-year.
Gross margin slipped as product mix shifted toward lower-margin emerging markets and new product launch costs landed.
The board held the interim dividend steady rather than lifting it, a decision that reads very differently with hindsight.
The revised guidance implies second-half underlying net profit of just $95 million to $135 million, which would be a decline of roughly 41% on the first half.
The balance sheet, at least, remains sound, with the company still sitting in a net cash position.
What Cochlear shares need to deliver on 18 August
Three things matter.
The first is landing within the revised guidance range. After a downgrade of that severity, credibility is the scarcest asset Cochlear has right now.
The second is Nexa, the company's smart cochlear implant. The bull case rests on Nexa driving share gains in developed markets through product differentiation, surgeon enthusiasm and higher average selling prices.
Investors will want evidence that this is actually happening rather than a repeat of the launch disruption seen in the first half.
The third is FY27 guidance and the cost base.
Management flagged in April that it was accelerating plans to reshape the cost base to create capacity to invest in growth.
Analyst sentiment reflects the uncertainty.
Morgans retained a hold rating but halved its price target to $107.17 from $214.93, noting:
COH has delivered a material downgrade to FY26 earnings, cutting guidance by c30% at the midpoint.
Foolish takeaway
Cochlear remains a high-quality business with a wide moat and roughly 50% of the global cochlear implant market. That has not changed.
What has changed is earnings visibility, which is now the weakest it has been in years.
The shares have already bounced from their lows but remain down around 53% in 2026.
Cochlear shares are cheap relative to their own history for a reason.
A rebound is entirely possible, but it likely needs two clean results, and 18 August is only the first of those.
